@article{cf1dc65d4f9c4936a00dab9f4f29cfd1,
title = "Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?",
author = "Landsburg, {Daniel J.} and Kahl, {Brad S.}",
note = "Funding Information: D. Landsburg reports research funding from Curis , Takeda , and Triphase ; consulting for Curis; and advisory board member for Celgene. B. Kahl reports consulting for Abbvie, Acerta, AstraZeneca, Bayer, BeiGene, Cell Therapeutics, Celgene, Genentech, Roche, Juno, and Unum; and research funding from Acerta , Genentech , and BeiGene . ",
year = "2019",
month = feb,
doi = "10.1016/j.clml.2018.11.017",
language = "English",
volume = "19",
pages = "65--67",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
number = "2",
}